Skip to main content

Table 1 Characteristics of the study cohort (elderly on asthma medicine)

From: Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified

Study group Total Mean age (SD)a Males (%) Montelukastb (%) Total drugs in DDDs (SD)c
All subjects 203,473 75.2 (9.7) 89,755 (44.1) 23,636 (11.6) 5.1 (4.6)
Montelukast 23,636 73.1 (9.0) 8964 (37.9) - 6.3 (4.3)
Dementia medicine 6453 83.6 (7.7) 2502 (38.8) 602 (9.3) 5.6 (3.2)
Nursing homed 5970 77.8 (10.4) 2463 (41.3) 507 (8.5) 4.2 (3.5)
Death 61,434 82.7 (9.5) 31,152 (50.7) 5514 (9.0) 7.1 (6.3)
Parkinson’s medicine 7140 76.1 (9.3) 2849 (39.9) 955 (13.4) 6.3 (3.9)
Diabetes medicine 23,747 74.8 (9.1) 11,920 (50.2) 2887 (12.2) 7.8 (4.3)
  1. aAge in 2014
  2. bAt least two prescriptions
  3. cMean Defined Daily Doses (DDDs) prescribed of any drug
  4. dIt was assumed that a majority of those who did not receive any prescription for more than a year were admitted to a nursing home. Living in a nursing home can be used as a proxy for cognitive decline in that some 80% of Norwegian nursing home residents have dementia [11]